SCHEMBL2434751

SCHEMBL2434751

N#Cc1c(O)nsc1Nc1cccc(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.48
RECQL P46063 1/20 0.48
ALDH1A1 P00352 5/20 0.45
MAPT P10636 4/20 0.45
KMT2A Q03164 4/20 0.45
MEN1 O00255 3/20 0.45
LMNA P02545 1/20 0.45
ALOX12 P18054 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
ADORA2A P29274 3/20 0.41
ALOX15 P16050 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HSD17B10 Q99714 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
CYP3A4 P08684 1/20 0.40
TSHR P16473 1/20 0.40
CISD1 Q9NZ45 1/20 0.40
EGFR P00533 1/20 0.40
ERBB2 P04626 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2436615 0.87 MAP2K1 (0.51) HTTRECQLALDH1A1MAPTKMT2A
SCHEMBL5941057 0.85 HTT (0.49) HTTRECQLALDH1A1MAPTKMT2A
SCHEMBL5941107 0.84 LMNA (0.51) HTTRECQLALDH1A1MAPTKMT2A
SCHEMBL2437731 0.84 HTT (0.55) HTTRECQLALDH1A1MAPTKMT2A
SCHEMBL5941015 0.84 MAP2K1 (0.54) HTTRECQLALDH1A1MAPTKMT2A
SCHEMBL1228956 0.83 MAPT (0.50) HTTRECQLALDH1A1MAPTKMT2A
SCHEMBL3527060 0.83 HTT (0.68) HTTRECQLALDH1A1MAPTKMT2A
SCHEMBL21917354 0.82 HTT (0.43) HTTRECQLALDH1A1MAPTKMT2A
SCHEMBL21917351 0.81 MAPT (0.45) HTTRECQLALDH1A1MAPTKMT2A
SCHEMBL13988271 0.81 HTT (0.45) HTTRECQLALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6989451-B2 Substituted isothiazole compounds are useful for treating the diseases associated with abnormality in protein kinases(especially MAP kinases) VALEANT RESEARCH & DEVELOPMENT (US) 2006-01-24 US claimed
EP-2362909-A2 MAMMALIAN GENES INVOLVED IN INFECTION Zirus, Inc. (US) 2011-09-07 EP disclosed
WO-2010039778-A2 MAMMALIAN GENES INVOLVED IN INFECTION Zirus, Inc. (US) 2010-04-08 WO disclosed
US-6989451-B2 Substituted isothiazole compounds are useful for treating the diseases associated with abnormality in protein kinases(especially MAP kinases) VALEANT RESEARCH & DEVELOPMENT (US) 2006-01-24 US disclosed
US-20040039037-A1 Heterocyclic compounds and uses thereof VALEANT PHARMA POLAND SPOLKA Z ORGANICZONA ODPOWIEDZIALNOSCIA (PL) 2004-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040039037-A1 Heterocyclic compounds and uses thereof MAP3K1, MAP3K20, MAP4K2 HTT 2684/4885RECQL 3054/4885ALDH1A1 2646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.